ESMO 2024 | CONTACT-03 and TiNivo-2: rethinking immunotherapy rechallenge in RCC
Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, discusses findings from two Phase III trials, CONTACT-03 (NCT04338269) and TiNivo-2 (NCT04987203), which show that immediately sequencing immune checkpoint inhibitors after progression provides no therapeutic benefit. Currently, patients progressing on these inhibitors are treated with single anti-angiogenic agents, though the optimal approach remains uncertain. Further studies are needed to evaluate long-term immunotherapy rechallenge strategies, suggesting that while immediate rechallenge is ineffective, exploring long-term strategies could offer new therapeutic options. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
